As previously discussed, the expression of additional immune checkpoint receptors such as LAG-3 or distinct expression levels of these immune checkpoints could also explain the unfavorable response rates to anti-CTLA-4 and anti-PD-1 therapies in uveal melanoma. Here, CTLA4 is linked to uveal melanoma.